​

MoonLake Immunotherapeutics (MLTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

MLTX Stock Forecast

MoonLake Immunotherapeutics (MLTX) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $67.00, with a high of $67.00 and a low of $67.00. This represents a 52.20% increase from the last price of $44.02.

$40 $46 $52 $58 $64 $70 High: $67 Avg: $67 Low: $67 Last Closed Price: $44.02

MLTX Stock Rating

MoonLake Immunotherapeutics stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 13 0 13 Strong Sell Sell Hold Buy Strong Buy

MLTX Price Target Upside V Benchmarks

TypeNameUpside
StockMoonLake Immunotherapeutics52.20%
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts-12
Avg Price Target-$67.00$83.50
Last Closing Price$44.02$44.02$44.02
Upside/Downside-52.20%89.69%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25412---16
May, 254111--16
Apr, 254111--16
Mar, 253111--15
Feb, 253111--15
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 18, 2025RBC Capital$67.00$40.8564.01%52.20%
Jul 01, 2024Raghuram SelvarajuH.C. Wainwright$100.00$43.97127.43%127.17%
Apr 02, 2024Richard LawGoldman Sachs$62.00$48.6027.57%40.85%
Aug 31, 2023Serge BelangerNeedham$76.00$56.1035.47%72.65%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 03, 2025CitigroupBuyBuyhold
May 19, 2025Wolfe ResearchPeer PerformOutperformupgrade
Jan 09, 2025BTIGBuyBuyhold
Oct 15, 2024H.C. WainwrightBuyBuyhold
Sep 12, 2024Cowen & Co.BuyBuyhold
Sep 12, 2024H.C. WainwrightBuyBuyhold
Aug 26, 2024Wolfe ResearchPeer Performdowngrade
Jul 01, 2024H.C. WainwrightBuyBuyhold
Jun 24, 2024OppenheimerOutperforminitialise
Apr 02, 2024Goldman SachsNeutralinitialise

Financial Forecast

EPS Forecast

$-2K $-2K $-1K $-500 $0 $500 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.73$-1.92K----
Avg Forecast$-0.90$-1.79$-2.77$-3.33$-3.63$0.80
High Forecast$-0.84$-1.61$-2.00$-2.09$-1.92$0.80
Low Forecast$-0.93$-1.92$-3.39$-4.31$-5.97$0.80
Surprise %-18.89%107135.20%----

Revenue Forecast

$100M $210M $320M $430M $540M $650M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast----$115.80M$645.41M
High Forecast----$120.20M$645.41M
Low Forecast----$111.40M$645.41M
Surprise %------

Net Income Forecast

$-150B $-110B $-70B $-30B $10B $50B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-36.01M$-120.68B----
Avg Forecast$-43.46M$-80.77M$-132.53M$-157.26M$-267.54M$39.13M
High Forecast$-41.39M$-79.04M$-98.31M$-102.62M$-94.19M$39.13M
Low Forecast$-45.53M$-94.16M$-166.76M$-211.90M$-293.19M$39.13M
Surprise %-17.15%149315.46%----

MLTX Forecast FAQ

Is MoonLake Immunotherapeutics stock a buy?

MoonLake Immunotherapeutics stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that MoonLake Immunotherapeutics is a favorable investment for most analysts.

What is MoonLake Immunotherapeutics's price target?

MoonLake Immunotherapeutics's price target, set by 13 Wall Street analysts, averages $67 over the next 12 months. The price target range spans from $67 at the low end to $67 at the high end, suggesting a potential 52.20% change from the previous closing price of $44.02.

How does MoonLake Immunotherapeutics stock forecast compare to its benchmarks?

MoonLake Immunotherapeutics's stock forecast shows a 52.20% upside, outperforming the average forecast for the healthcare stocks sector (23.68%) and underperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for MoonLake Immunotherapeutics over the past three months?

  • June 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 25.00% Strong Buy, 68.75% Buy, 6.25% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 25.00% Strong Buy, 68.75% Buy, 6.25% Hold, 0% Sell, 0% Strong Sell.

What is MoonLake Immunotherapeutics’s EPS forecast?

MoonLake Immunotherapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.77, marking a -99.86% decrease from the reported $-1.92K in 2024. Estimates for the following years are $-3.33 in 2026, $-3.63 in 2027, and $0.8 in 2028.

What is MoonLake Immunotherapeutics’s revenue forecast?

MoonLake Immunotherapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $0, followed by $115.8M for 2027, and $645.41M for 2028.

What is MoonLake Immunotherapeutics’s net income forecast?

MoonLake Immunotherapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-133M, representing a -99.89% decrease from the reported $-121B in 2024. Projections indicate $-157M in 2026, $-268M in 2027, and $39.13M in 2028.